Odimma-therapeutics

We are a startup (creation 2017) from Strasbourg developing a proprietary platform dedicated to personalized cancer treatment, based on the disruptive technology of synthetic DNA and advanced algorithms. 

We claim to be able to bring this type of treatment at affordable cost to patients in a shortened timeframe (8 weeks), compatible with clinical management and at an acceptable cost for our healthcare systems.  

Unsuccessful attempts at personalized immunotherapy have been made in the past, but the neoantigens identified at the time were similar to the Ag of the self and as such were not recognized by the immune system as a foreign agent due to -probably among other factors- much less impressive artificial intelligence, and training data in smaller quantities on the one hand, but especially less relevant since they came mainly from viral epitopes. 

Since its creation, Odimma-therapeutics has accumulated proof of concept with preclinical results superior to those presented by the competition and has built a qualified team thanks to which we are now on the eve of the first in man clinical trial (end 2024). 

Our complex supply chain is secure, we have GMP clinical batches thanks to partnerships with European suppliers. 

Today, we are trying to further finance the clinical development of the product (Extension seed round 5MioE in 2024 and a series A in 2025). 

We have been awarded the prize for the "most innovative start-up for health in Europe" at Biofit 2022 and we are supported by a regional seed fund (Cap Inovest) and by the BPI. 

We have an ambitious and solid project.